Immunotherapy plus chemo then immediate vs selective re-radiation for advanced recurrent NPC
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial is for people with nasopharyngeal cancer that has come back in the same area. It tests whether giving additional radiation right after chemo plus immunotherapy works better than waiting to see if more radiation is needed later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your cancer must have returned more than one year after initial treatment and cannot be removed with surgery.
- Your cancer type must be non-keratinizing nasopharyngeal carcinoma (a specific subtype).
- You must have had at least some shrinkage of the tumor after 4 to 6 cycles of chemo plus a PD-1 inhibitor (a type of immunotherapy).
- You must be well enough to do daily activities (ECOG score 0 or 1).
- You cannot have received any prior treatment for the recurrent cancer, including radiation, chemo, or immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving radiation therapy to the main tumor right after chemo-immunotherapy is better than waiting until the cancer comes back, in people with newly diagnosed metastatic nasopharyngeal cancer. It aims to see which approach helps you live longer and have fewer side effects.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial studies whether adding a PD-1 antibody (an immunotherapy) to standard chemoradiation can better control recurrent nasopharyngeal cancer that can’t be removed with surgery. If you qualify, you’d receive the study treatment and be closely monitored for side effects and cancer response.
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
Hear when a new Nasopharangeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.